News for CanSino Biologics Inc. (688185.SS)

Recently, CanSinoBIO initiated a Phase Ⅲ clinical trial of its Group ACYW135 Meningococcal Conjugate Vaccine Menhycia®, successfully enrolling its first participant in Indonesia. This trial aims...

December 18, 2023 - CanSino Biologics Inc. , a leading Chinese biopharmaceutical company with a strong track record in the research, production, and commercialization of groundbreaking...

Certain A Shares of CanSino Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2023. These A Shares will be under lockup for 1105 days starting from 3-AUG-2020 to... -Yesterday at 06:00 pm- MarketScreener

CanSino Biologics Inc. announced that, the Recombinant Zoster Vaccine developed by the Group in co-operation with Vaccitech Limited has received a No Objection Letter for clinical trials from Health...

/PRNewswire/ -- The vaccine research market size is estimated to grow by USD 17.59 billion from 2022 to 2027 at a CAGR of 9.88%, according to Technavio. The...

Fosun Pharma’s revenue grew slightly in the first quarter on its diverse product portfolio, while its net profit soared by 116%.

The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades.

PUTRAJAYA: The National Pharmaceutical Regulatory Agency (NPRA) has approved an application from Solution Biologics Sdn Bhd, regarding the extension o...

Key Takeaways: After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland Sales could surge for the company’s Covid-19 vaccines as China launches a nationwide campaign for a new round of boosters By Molly Wen

After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland.

Winter’s nearly over and the Covid surge in Australia has slowed down dramatically. New cases are now rapidly declining.

The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.

/PRNewswire/ -- The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of...

DUBLIN, July 30, 2021 /PRNewswire/ -- The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product

Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine …

BEIJING — China’s medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical…

A botched deal last year between Canada and Chinese vaccine manufacturer CanSino Biologics Inc. laid bare this country’s vulnerabilities amid efforts to devise a proper immunization plan.

When the Trudeau government spent big to pre-order vaccines, it said Canada would be well prepared. But now, Canadian inoculation rates are behind peer nations, as experts say federal officials put too much faith in global supply chains

The first batch of 2 million vaccines from China's CanSino Biologics Inc , produced in Mexico, will be ready in the second half of March, the company said on Sunday. Mexico in early February received its first shipment of the active ingredient for the shot, which is being packaged in Queretaro state by Mexican firm Drugmex, CanSino said in a statement. Mexico has so far received Pfizer, AstraZeneca, Sputnik V and Sinovac vaccines.